6 completed. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
Follow Cosmo Technologies Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Rifamycin SV 600mg t.i.d., Rifamycin SV b.i.d. + Placebo, Placebo t.i.d. - Diarrhea-predominant Irritable Bowel Syndrome | Phase 2 | Completed | Cosmo Technologies Ltd | 279 | 2017-12-18 | 2021-01-08 |
| Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA standard white light colonoscopy-equivalent to placebo, Methylene Blue MMX tablets - Colorectal Cancer | Phase 2 | Completed | Cosmo Technologies Ltd | 10 | 2013-02-01 | 2018-11-05 |
| Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy oral delivery mucosal stain - Ulcerative Colitis | Phase 2 | Completed | Cosmo Technologies Ltd | 53 | 2012-01-01 | 2019-02-08 |
| Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX Methylene Blue MMX 25 mg modified release tablets - Colon Staining in Preparation for Colonoscopy | Phase 2 | Completed | Cosmo Technologies Ltd | 114 | 2011-05-02 | 2021-01-28 |
| Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea 400 mg Rifamycin SV dosage, 800 mg Rifamycin SV dosage, 1200 mg Rifamycin SV dosage - Infectious Diarrhoea | Phase 2 | Completed | Cosmo Technologies Ltd | 40 | 2008-02-01 | 2020-02-18 |
| Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy Sigmoidoscopy - Ulcerative Colitis | Phase 2 | Completed | Cosmo Technologies Ltd | 133 | 2007-01-01 | 2009-03-25 |
Colitis, Ulcerative (2) · Colorectal Neoplasms (1) · Dysentery (1)
Sigmoidoscopy (1) · rifamycin SV (1)
Italy (3) · Belgium (1) · Germany (1) · Spain (1)
Alessandro Repici, MD (1) · Antonio Gasbarrini, Prof (1) · Manuel Mancera Reyes (1) · Silvio Danese, MD (1)